The Tanreqing Injection developed and produced by Shanghai Kaibao Pharmaceutical Co., Ltd. has successively won the "National Modern Traditional Chinese Medicine High-tech Industrialization Demonstration Project" from the National Development and Reform Commission; Shanghai's key new anti-SARS product "Shanghai Famous Products in the Pharmaceutical Industry", Shanghai High-tech Achievements (A) Level Transformation Project, National Ministry of Science and Technology Innovation Fund Support Project; Shanghai Science and Technology Progress Third Prize; National Development and Reform Commission "Reserve Catalog of Chinese Patent Medicines for Influenza Prevention and Treatment" "Influenza Prevention and Treatment" Reserved Drugs"; Shanghai Brand Products; Shanghai Patented New Products; Shanghai's Top 100 High-tech Achievements Transformation Projects and Top Ten Independent Innovation Projects; "Shanghai Famous Brand Products"; Listed as "Human Avian Influenza Diagnosis and Treatment Plan" by the Ministry of Health Medication; In 2009, it was listed as a clinically designated drug by the Ministry of Health and the State Administration of Traditional Chinese Medicine in the "Clinical Technical Guidelines for the Prevention and Treatment of Hand, Foot and Mouth Disease with Traditional Chinese Medicine" and the "Diagnosis and Treatment Plan for Influenza A (H1N1) (2009 Trial Version 2)". Tanreqing injection has been widely recognized by doctors and patients, and has become a well-known product brand, with market performance leading among similar products.